Tenderwize
Retour à la recherche

Open House Originale Rabattverträge 2024-12 - Tofacitinib

Techniker Krankenkasse·Hamburg, Germany·Deadline Dec 29, 2026 · 125 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-12 - Tofacitinib

60/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

30 / 100

Facteurs de risque

No estimated value or framework maximum is given. The potential volume and revenue are unknown, making financial planni...

The contract terminates automatically upon patent expiry or loss of market exclusivity. If your patent is expiring soon...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclude discount agreements (Rabattverträge) for Tofacitinib under §130c Abs.1 SGB V
  • Supply of Tofacitinib pharmaceutical products to insured persons of TK and participating insurers
Afficher le résumé complet

This Open House procedure by Techniker Krankenkasse (TK) and other German health insurers invites all eligible pharmaceutical entrepreneurs to conclude discount agreements (Rabattverträge) for the active substance Tofacitinib. The contract runs from 1 January 2025 to 31 December 2026, with no exclusivity and standardised conditions. No estimated contract value is provided. Submission is possible at any time during the contract period via email or post, but must be signed with a qualified electronic signature or as a scanned original. This is not a traditional public procurement but a voluntary open house model.

Risques

No estimated value or framework maximum is given. The potential volume and revenue are unknown, making financial planni...

The contract terminates automatically upon patent expiry or loss of market exclusivity. If your patent is expiring soon...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in §4 Abs.18 AMG
  • Must have a valid marketing authorisation for Tofacitinib in Germany or be otherwise entitled to market the product

Eligibility

  • Must confirm no exclusion grounds under §123 and §124 GWB (legal convictions/events)

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Originale Rabattverträge 2024-12 - Tofacitinib

Discount agreement for Tofacitinib. The buyer aims to conclude agreements with all suitable pharmaceutical entrepreneurs. No individual negotiations; uniform conditions apply. Non-exclusive contract available to all eligible parties. Contract duration max 24 months, starting 1 January 2025 and ending no later than 31 December 2026. Early termination upon patent expiry.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Dec 2024 - Dec 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Dec 31, 2026

Détails de la procédure

Date de publication
17 Nov 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
702362-2024

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3